AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary endpoints in the BaxHTN Phase III trial, effectively lowering blood pressure ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

The deal will see Apple and MP Materials launch a recycling facility for processing recycled rare earth elements. Once ...

The 24-year study of more than 1.2 million children in Denmark found that aluminum exposure didn't raise the risk of autism, asthma, or other chronic diseases. Other science and research news is on ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

The phase 3 BaxHTN trial has been evaluating two doses of the drug in patients with uncontrolled hypertension being treated ...

AstraZeneca’s Phase III BaxHTN trial shows that baxdrostat significantly lowers systolic blood pressure in resistant ...

AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial, indicating that the highly selective aldosterone synthase inhibitor (ASI), baxdrostat, significantly reduced the mean seated ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

FRANKFURT: European shares ended slightly lower on Monday, with tariff-sensitive auto stocks down after US President Donald ...